Evidence map›Paper›PMID 39503494›Full record

ArticleJournal of clinical microbiology2024

Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2

Alexander L Greninger, Allan Larcena, Amrish Patel, Brian Webster, Christina Ulen, Dallas F Green, Dana King, Deepesh Rubin Patel, Erin McElvania, Glenn Harnett and 17 more

Abstract readMulticenter StudyEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Alexander L GreningerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-7443-0527
Allan LarcenaSlidell Internal Medicine Clinic, Slidell, Louisiana, USA.
Amrish PatelInnovo Research - Piedmont Healthcare, Troutman, North Carolina, USA.
Brian WebsterInnovo Research - Wilmington Health, Wilmington, North Carolina, USA.
Christina UlenAdvanced Pediatrics, Vienna, Virginia, USA.
Dallas F GreenAHF - The Kinder Medical Group, Miami, Florida, USA.
Dana KingUniversity of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Deepesh Rubin PatelPatient Plus Urgent Care - Southdowns, Baton Rouge, Louisiana, USA.
Erin McElvaniaDepartment of Pathology and Laboratory Medicine, Endeavor Health, Evanston, Illinois, USA.ORCID 0009-0007-3959-2583
Glenn HarnettNo Resistance Consulting Group, Birmingham, Alabama, USA.
Imad JandaliASCLEPES Research Centers, Brooksville, Florida, USA.
Jane GibsonUCF Student Health Services, Orlando, Florida, USA.
Jennifer KillionMcFarland Clinic - PC, Ames, Iowa, USA.
Jibran AtwiMedPharmics LLC, Lafayette, Louisiana, USA.
Kelly BergmannChildren's of Minnesota, Minneapolis, Minnesota, USA.
Lance SladeMeridian Clinical Research LLC, Macon, Georgia, USA.
Mary Allen StaatCincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, USA.
Matthew FaronFroedtert & the Medical College of Wisconsin Hospitals and Health Partners, Milwaukee, Wisconsin, USA.
Megan WashingtonTrustCare I-55, Jackson, Mississippi, USA.
Rahul PatelMeridian Clinical Research LLC, Rockville, Maryland, USA.
Rajasekaran AnnamalaiPCP for Life-Tidwell, Houston, Texas, USA.
Ronald AckermanComprehensive Clinical Research LLC, West Palm Beach, Florida, USA.
William P StewartFord, Simpson, Lively & Rice Pediatrics PLLC, Winston-Salem, North Carolina, USA.
Yuliet Mora AmadorSanta Clara Family Clinic, Houston, Texas, USA.
Deepa RaoCepheid, Sunnyvale, California, USA.
Xiaohong LiuCepheid, Sunnyvale, California, USA.
Aarthi RamanCepheid, Sunnyvale, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues its largely aseasonal spread with millions of cases per year. Highly sensitive, point-of-care testing is critical for rapid detection of coronavirus disease 2019 (COVID-19) cases and initiation of antiviral therapy to avert adverse health outcomes and reduce onward transmission of the virus. While hundreds of COVID-19 diagnostics received emergency use authorization from the FDA during the pandemic, significantly fewer have navigated the course to FDA clearance or approval. Here, we determined the clinical performance of the Cepheid Xpert Xpress CoV-2 IMPORTANCE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause millions of infections and tens of thousands of deaths per year in the United States. While the FDA authorized hundreds of SARS-CoV-2 tests during the public health emergency, significantly fewer have made the transition to being cleared or approved. There continues to be a need for FDA-authorized point-of-care SARS-CoV-2 testing that can be performed by untrained users. We conducted a large prospective study of the Cepheid Xpert Xpress CoV-2

Indexed as

COVID-19NasopharynxPoint-of-Care TestingSARS-CoV-2AdolescentAdultAgedAged, 80 and overChildChild, PreschoolCOVID-19 Nucleic Acid TestingCOVID-19 TestingFemaleHumansInfantMaleCepheidclinical studyCOVID-19point-of-carerapidSARS-CoV-2Xpert Xpress

Identifiers

PMID39503494
PMCPMC11633094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.